Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ITGR
ITGR logo

ITGR Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Integer Holdings Corp (ITGR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
90.960
1 Day change
1.63%
52 Week Range
123.780
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Integer Holdings Corp (ITGR) is not a strong buy at the moment for a beginner, long-term investor. While the stock has some positive catalysts, such as recent analyst upgrades and favorable private equity interest, the lack of strong technical indicators, absence of significant trading signals, and the neutral sentiment from hedge funds and insiders suggest holding off for now.

Technical Analysis

The MACD is below 0 and negatively contracting, indicating weak momentum. RSI is neutral at 49.693, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 91.859, with support at 89.779 and resistance at 93.939.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
9

Positive Catalysts

  • Analyst upgrades: Oppenheimer upgraded the stock to Outperform with a $115 price target, citing private equity interest and favorable risk-reward.

  • Strategic review process and strong fundamentals in the medical technology sector.

  • Favorable long-term growth potential in the EP market.

Neutral/Negative Catalysts

  • Lack of strong technical signals and neutral sentiment from hedge funds and insiders.

  • Reduced FY26 guidance despite Q1 revenue beat.

  • Uncertainty in the macro environment and concerns about private credit exposure for private equity funds.

Financial Performance

No financial data available for the latest quarter, making it difficult to assess recent growth trends.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have mixed views. Recent upgrades include Oppenheimer's Outperform rating with a $115 price target. However, Citi maintains a Neutral rating with a $92 price target, and Piper Sandler raised the target to $97 while expressing caution about stabilization timelines.

Wall Street analysts forecast ITGR stock price to fall
4 Analyst Rating
Wall Street analysts forecast ITGR stock price to fall
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 89.500
sliders
Low
75
Averages
86.25
High
95
Current: 89.500
sliders
Low
75
Averages
86.25
High
95
Citi
Joanne Wuensch
Neutral
maintain
$89 -> $92
AI Analysis
2026-05-28
Reason
Citi
Joanne Wuensch
Price Target
$89 -> $92
AI Analysis
2026-05-28
maintain
Neutral
Reason
Citi analyst Joanne Wuensch raised the firm's price target on Integer to $92 from $89 and keeps a Neutral rating on the shares. The firm updated models in the medical technology space post the Q1 reports. Citi believes fundamentals in the sector remain solid.
Oppenheimer
Suraj Kalia
Perform
to
Outperform
upgrade
$115
2026-05-13
Reason
Oppenheimer
Suraj Kalia
Price Target
$115
2026-05-13
upgrade
Perform
to
Outperform
Reason
As previously reported, Oppenheimer analyst Suraj Kalia upgraded Integer to Outperform from Perform with a $115 price target. The firm notes Integer recently announced a strategic review process, with the stock having recovered only a little from its end-2025 drop. Considering this and private equity interest in the contract manufacturing organization space, Oppenheimer embarked on field checks with its CMO industry contacts and returned with a better appreciation of private equity interest in the space in general. The firm's channel checks, in the context of the strategic review and Integer's year-end sell-off, suggest a favorable risk-reward at these levels, with limited downside to numbers. However, Integer notes the macro-level environment remains highly uncertain and dislocations can happen overnight and private credit exposure for PE funds remains a concern.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ITGR
Unlock Now

People Also Watch